학술논문
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
Document Type
Article
Author
Paton, Nicholas I; Musaazi, Joseph; Kityo, Cissy; Walimbwa, Stephen; Hoppe, Anne; Balyegisawa, Apolo; Asienzo, Jesca; Kaimal, Arvind; Mirembe, Grace; Lugemwa, Abbas; Ategeka, Gilbert; Borok, Margaret; Mugerwa, Henry; Siika, Abraham; Odongpiny, Eva Laker A; Castelnuovo, Barbara; Kiragga, Agnes; Kambugu, Andrew; Kambugu, Andrew; Kaimal, Arvind; Castelnuovo, Barbara; Kiiza, Daniel; Asienzo, Jesca; Kisembo, John; Nsubuga, John; Okwero, Max; Muyise, Rhona; Kityo, Cissy; Nasaazi, Claire; Nakiboneka, Dridah L.; Mugerwa, Henry; Namusanje, Josephine; Najjuuko, Theresa; Masaba, Timothy; Serumaga, Timothy; Alinaitwe, Adolf; Arinda, Allan; Rweyora, Angela; Ategeka, Gilbert; Kangah, Mary Goretti; Lugemwa, Abbas; Kasozi, Mariam; Tukumushabe, Phionah; Akunda, Rogers; Makumbi, Shafic; Musumba, Sharif; Myalo, Sula; Ahuura, John; Namusisi, Annet Mary; Kibirige, Daniel; Kiweewa, Francis; Mirembe, Grace; Mabonga, Habert; Wandege, Joseph; Nakakeeto, Josephine; Namubiru, Sharon; Nansalire, Winfred; Siika, Abraham Mosigisi; Kwobah, Charles Meja; Mboya, Chris Sande; Mokaya, Martha Mokeira Bisieri; Karoney, Mercy Jelagat; Cheruiyot, Priscilla Chepkorir; Cherutich, Salinah; Njuguna, Simon Wachira; Kirui, Viola Cherotich; Borok, Margaret; Chidziva, Ennie; Musoro, Godfrey; Hakim, James; Bhiri, Joyline; Phiri, Misheck; Mudzingwa, Shepherd; Manyanga, Tadios; Kiragga, Agnes; Banegura, Anchilla Mary; Hoppe, Anne; Balyegisawa, Apolo; Agwang, Betty; Isaaya, Brian; Tumwine, Constantine; Odongpiny, Eva Laker A.; Asienzo, Jesca; Musaazi, Joseph; Paton, Nicholas; Senkungu, Peter; Walimbwa, Stephen; Kamara, Yvonne; Amperiize, Mathius; Allen, Elizabeth; Opondo, Charles; Mohammed, Perry; van Rein-van der Horst, Willemijn; Van Delft, Yvon; Boateng, Fafa Addo; Namara, Doreen; Kaleebu, Pontiano; Ojoo, Sylvia; Bwakura, Tapiwanashe; Katana, Milly; Venter, Francois; Phiri, Sam; Walker, Sarah
Source
The Lancet HIV; June 2022, Vol. 9 Issue: 6 pe381-e393, 13p
Subject
Language
ISSN
24054704; 23523018
Abstract
WHO guidelines recommend dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first-line tenofovir to zidovudine. We aimed to examine whether dolutegravir is non-inferior to darunavir, the best-in-class protease inhibitor drug, and whether maintaining tenofovir in second-line therapy is non-inferior to switching to zidovudine.